AMIKACIN IN DOGS
What the Literature Actually Says
BOTTOM LINE
Amikacin really can be nephrotoxic — but the risk is strongly related to dose, duration, hydration, renal function, and dosing interval.
The available canine literature does not demonstrate a high incidence of clinical renal failure in healthy, well-hydrated dogs receiving a short therapeutic course of amikacin.
Modern once-daily dosing is intended to provide a high antibacterial peak followed by a prolonged low or essentially drug-free trough.
PRACTICAL CANINE DOSE
Amikacin: 15 mg/kg IV, IM, or SC every 24 hours
Current ISCAID canine guidelines use 15 mg/kg q24h. Higher once-daily doses have been described in particular pharmacokinetic circumstances, but routine escalation is not necessary simply because the drug is an aminoglycoside.
Older UTI guidelines list 15–30 mg/kg q24h.
Avoid routine use in dehydrated, hypotensive, or renally compromised patients unless the expected benefit clearly outweighs the risk.
WHAT ACTUALLY HAPPENED IN DOGS?
| Exposure | Actual result |
|---|---|
| 80 infected dogs: amikacin 10 mg/kg q12h for 8–21 days | 0/80 had recognized clinical nephrotoxicity or other toxicity. |
| Amikacin 45 mg/kg/day for 14 days | Minimal-to-mild renal histopathologic changes. |
| Amikacin 30 mg/kg/day for 90 days | Minimal renal alterations considered reversible; urinary casts were not reported. |
| Amikacin 200 mg/kg/day | Renal injury in 5/10 dogs. |
| Amikacin 400 mg/kg/day | Renal injury in all dogs; 3 died after 14–17 days. |
| Gentamicin 6 mg/kg q24h × 5 days, 6 healthy dogs | No clinically important nephrotoxicity. Minor changes: slight BUN/creatinine increase in 1, decreased USG in 1, a few granular casts in 2. |
| Gentamicin 10 mg/kg q8h = 30 mg/kg/day × 10 days | Deliberately nephrotoxic regimen. Urinary GGT rose by day 5; significant creatinine elevation occurred around day 9. |
| Gentamicin 8–10 mg/kg q8h | Used specifically to induce experimental AKI in dogs. |
THE IMPORTANT DISTINCTION
Many classic “aminoglycosides are nephrotoxic” experiments used approximately:
Gentamicin 24–30 mg/kg PER DAY, divided every 8 hours, for 8–10+ days.
That exposure is not equivalent to amikacin 15 mg/kg once daily for several days.
These studies prove that aminoglycosides can produce proximal tubular injury. They do not establish a high incidence of renal failure during a short, appropriately dosed clinical course.
PRACTICAL 5–7 DAY AMIKACIN PROTOCOL
BEFORE FIRST DOSE
1. Confirm a good indication
Preferably culture-supported infection where amikacin offers a meaningful advantage.
2. Check hydration/perfusion
Correct clinically significant dehydration or hypotension before dosing whenever possible.
3. Establish renal baseline
- Creatinine
- BUN
- Electrolytes
- Urinalysis
- USG
- Urine sediment for casts
SDMA can be included if readily available, but don’t delay necessary therapy waiting for it.
4. Review concurrent medications
Avoid unnecessary simultaneous nephrotoxic/nephroactive drugs, particularly NSAIDs, other aminoglycosides, cisplatin, cyclosporine and aggressive diuretic therapy.
TREATMENT
Amikacin 15 mg/kg IV/IM/SC q24h
Maintain reasonable hydration.
Use the shortest effective course based upon infection site, clinical response and culture data.
DAY 3–5
Current ISCAID guidance specifically recommends checking urine every 3–5 days for:
- falling USG
- granular casts
These may appear before conventional azotemia.
For a hospitalized/high-risk patient, checking creatinine and urine parameters more frequently is reasonable.
DAY 5–7
Recheck:
- Creatinine
- BUN
- USG
- Urine sediment
- Hydration/perfusion
- Clinical response
If treatment must continue beyond approximately one week, renal monitoring becomes increasingly important. ISCAID recommends serum biochemistry before treatment and at least every 7–10 days during therapy.
WHEN I WOULD STOP AND REASSESS
Be concerned by a developing pattern of:
↑ creatinine
↓ urine concentrating ability
new granular casts
glycosuria without hyperglycemia
declining urine production
unexpected aminoglycoside accumulation
Creatinine is a late marker of aminoglycoside tubular damage; canine experimental studies demonstrate that urinary markers can become abnormal several days before marked serum creatinine elevation.
OPTIONAL THERAPEUTIC DRUG MONITORING
For longer courses, unusual volume of distribution, renal uncertainty, or critically ill patients, serum drug monitoring can provide additional safety.
Amikacin is rapidly eliminated in dogs with normal renal function; more than 90% of a dose was recovered in urine within 6 hours in a canine pharmacokinetic study.
The most useful principle is:
High peak — very low trough.
Persistent aminoglycoside exposure is undesirable.
WHAT CAN WE HONESTLY TELL A CLIENT OR CLINICIAN?
“Amikacin has genuine nephrotoxic potential, so kidney function should be considered and monitored. However, the canine literature does not show that short-course therapeutic amikacin commonly causes clinical renal failure in otherwise healthy, hydrated dogs. Much of the dramatic nephrotoxicity literature involves substantially higher doses, divided dosing, prolonged exposure, or protocols intentionally designed to create kidney injury.”
KEY REFERENCES
Loeffler A, et al. ISCAID antimicrobial use guidelines for canine pyoderma. Veterinary Dermatology. 2025.
Baggot JD, Ling GV, Chatfield RC. Clinical pharmacokinetics of amikacin in dogs. Am J Vet Res. 1985;46:1793–1796.
Greco DS, et al. Urinary gamma-glutamyl transpeptidase activity in dogs with gentamicin-induced nephrotoxicity. Am J Vet Res. 1985;46:2332–2335.
Gentamicin once-daily pharmacokinetic/renal safety study: 6 mg/kg IM q24h for five days in healthy dogs.
Amikacin canine regulatory efficacy/toxicology data: 80 infected dogs treated at 10 mg/kg q12h for 8–21 days without recognized nephrotoxicity.
